Dr. Craig S. Boddy
Claim this profileHawaii Cancer Care - Savio
Studies Leukemia
Studies Lymphoid Leukemia
7 reported clinical trials
35 drugs studied
Area of expertise
1Leukemia
BCR-ABL1 positive
Stage I
Stage II
2Lymphoid Leukemia
BCR-ABL1 positive
Philadelphia chromosome positive
Stage I
Affiliated Hospitals
Clinical Trials Craig S. Boddy is currently running
Blinatumomab + Chemotherapy
for Leukemia
This phase III trial compares the effect of usual treatment of chemotherapy and steroids and a tyrosine kinase inhibitor (TKI) to the same treatment plus blinatumomab. Blinatumomab is a Bi-specific T-Cell Engager ('BiTE') that may interfere with the ability of cancer cells to grow and spread. The information gained from this study may help researchers determine if combination therapy with steroids, TKIs, and blinatumomab work better than the standard of care.
Recruiting2 awards Phase 310 criteria
Oral Azacitidine + R-miniCHOP
for Diffuse Large B-Cell Lymphoma
This phase II/III trial compares the side effects and activity of oral azacitidine in combination with the standard drug therapy (reduced dose rituximab-cyclophosphamide, doxorubicin, vincristine, and prednisone \[R-miniCHOP\]) versus R-miniCHOP alone in treating patients 75 years or older with newly diagnosed diffuse large B cell lymphoma. R-miniCHOP includes a monoclonal antibody (a type of protein), called rituximab, which attaches to the lymphoma cells and may help the immune system kill these cells. R-miniCHOP also includes prednisone which is an anti-inflammatory medication and a combination of 3 chemotherapy drugs, cyclophosphamide, doxorubicin, and vincristine. These 3 chemotherapy drugs, as well as oral azacitidine, work in different ways to stop the growth of cancer cells, either by killing the cells, by stopping them from dividing, or by stopping them from spreading. Combining oral azacitidine with R-miniCHOP may shrink the cancer or extend the time without disease symptoms coming back or extend patient's survival when compared to R-miniCHOP alone.
Recruiting1 award Phase 2 & 314 criteria
More about Craig S. Boddy
Clinical Trial Related5 years of experience running clinical trials · Led 7 trials as a Principal Investigator · 3 Active Clinical TrialsTreatments Craig S. Boddy has experience with
- Vincristine Sulfate
- Cyclophosphamide
- Methotrexate
- Rituximab
- Cytarabine
- Dexamethasone
Breakdown of trials Craig S. Boddy has run
Leukemia
Lymphoid Leukemia
Lymphoma
Lymphoblastic Leukemia-Lymphoma
Other Doctors you might be interested in
Frequently asked questions
Do I need insurance to participate in a trial?
Almost all clinical trials will cover the cost of the ‘trial drug’ — so no insurance is required for this. For trials where this trial drug is given alongside an already-approved medication, there may be a cost (which your insurance would normally cover).
What does Craig S. Boddy specialize in?
Craig S. Boddy focuses on Leukemia and Lymphoid Leukemia. In particular, much of their work with Leukemia has involved BCR-ABL1 positive patients, or patients who are Stage I.
Is Craig S. Boddy currently recruiting for clinical trials?
Yes, Craig S. Boddy is currently recruiting for 3 clinical trials in 'Aiea Hawaii. If you're interested in participating, you should apply.
Are there any treatments that Craig S. Boddy has studied deeply?
Yes, Craig S. Boddy has studied treatments such as Vincristine Sulfate, Cyclophosphamide, Methotrexate.
What is the best way to schedule an appointment with Craig S. Boddy?
Apply for one of the trials that Craig S. Boddy is conducting.
What is the office address of Craig S. Boddy?
The office of Craig S. Boddy is located at: Hawaii Cancer Care - Savio, 'Aiea, Hawaii 96701 United States. This is the address for their practice at the Hawaii Cancer Care - Savio.
Is there any support for travel costs?
The coverage of travel expenses can vary greatly between different clinical trials. Please see more financial detail in the trials you’re interested to apply.